Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Imatinib AND Gleevec

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: Imatinib AND Gleevec. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2010-019568-35 Sponsor Protocol Number: OPTIM IMATINIB Start Date*: 2010-06-14
    Sponsor Name:CH VERSAILLES
    Full Title: A prospective randomized phase II study evaluating the monitoring of imatinib mesylate (Gliveec®) plasmatic through level in patients newly diagnosed with chronic phase chronic myelogenous leukaemi...
    Medical condition: Chronic Phase Chronic myelogenous leukemia (CP CML)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004758-34 Sponsor Protocol Number: CAMN107G2301 Start Date*: 2009-03-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open-label, multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tu...
    Medical condition: adult patients with histologically confirmed unresectable or metastatic GIST, either who have not received any prior anti-neoplastic therapy or, who experienced recurrence of GIST > 6 months after ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed) SK (Completed) CZ (Completed) SE (Completed) HU (Completed) NL (Completed) DE (Completed) FR (Completed) IT (Completed) GB (Completed) DK (Prematurely Ended) GR (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2004-004450-96 Sponsor Protocol Number: CA180-017 Start Date*: 2005-01-25
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Randomized Multi-center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have D...
    Medical condition: Chronic phase Philadelphia-Chromosome Positive (Ph+) Chronic Myeloid leukemia (CML)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed) DE (Completed) HU (Completed) FI (Completed) GB (Completed) IE (Completed) DK (Completed) EE (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000208-34 Sponsor Protocol Number: CAMN107A2303 Start Date*: 2007-06-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase III multi-center, open label, randomised study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chr...
    Medical condition: Adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009015 Chronic myeloid leukemia LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009013 Chronic myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) BE (Completed) IT (Completed) ES (Completed) SK (Completed) AT (Completed) FR (Completed) NL (Completed) FI (Completed) DK (Completed) DE (Completed) PT (Prematurely Ended) HU (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002601-69 Sponsor Protocol Number: CA180-013 Start Date*: 2005-01-25
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Phase II Study to Determine the Activity of BMS-354825 in Subjects with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease that is Resistant to High Dose Ima...
    Medical condition: Chronic phase Philadelphia chromosome-positive chronic myeloid leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) SE (Completed) FI (Completed) GB (Completed) IE (Completed) IT (Completed) BE (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-005153-22 Sponsor Protocol Number: CA180-043 Start Date*: 2006-07-24
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An open-label, randomized study of dasatinib vs. high-dose (800 mg) imatinib in the treatment of subjects with chronic phase chronic myeloid leukemia who have had a suboptimal response after at lea...
    Medical condition: Subjects with Ph+ chronic phase Chronic Myeloid leukemia (CML)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) DK (Prematurely Ended) PT (Completed) BE (Completed) DE (Completed) GB (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-011675-79 Sponsor Protocol Number: ACTIM Start Date*: 2009-07-10
    Sponsor Name:CH-Versailles
    Full Title: A PHASE II STUDY TO ASSESS EFFICACY AND SAFETY OF PIOGLITAZONE (ACTOS®) AS ADD-ON THERAPY TO IMATINIB MESYLATE (GLEEVEC®) IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) PATIENTS IN MAJOR...
    Medical condition: chronic phase chronic myelogenous leukaemia (CP-CML) patients in major molecular response.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000881-10 Sponsor Protocol Number: CSTI571AAT06 Start Date*: 2005-03-08
    Sponsor Name:CELSG (Central European Leukemia Study Group)
    Full Title: International, multicenter, randomised, open-labeled, 2-arm - Phase III Study comparing Imatinib (STI571, Glivec®) Standard Dose (400 mg/day) with Imatinib High Dose Induction (800 mg/day) followed...
    Medical condition: patients with chronic myelogenous leukemia in chronic phase (Ph+/BCR-ABL+)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001483-51 Sponsor Protocol Number: CAMN107A2101 Start Date*: 2005-07-12
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec (imatinib)-resistant/intolerant CML in chronic or accelerated ph...
    Medical condition: CML in chronic phase, accelerated phase or blast crisis, relapsed/refractory Ph+ ALL, systemic mastocytosis, or hypereosinophilic syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009700 CML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) SE (Completed) IT (Completed) DK (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-005712-27 Sponsor Protocol Number: CA180056 Start Date*: 2007-08-01
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: An Open-Label, Randomized, Multicenter Phase III Trial of Dasatinib (SPRYCEL®) vs. Standard Dose Imatinib (400 mg) in the Treatment of Subjects with Newly Diagnosed Chronic Phase Philadelphia Chrom...
    Medical condition: Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054352 Chronic phase chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) GR (Completed) BE (Completed) NL (Completed) DE (Completed) AT (Completed) HU (Completed) ES (Completed) IT (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-001818-41 Sponsor Protocol Number: CAMN107A2109 Start Date*: 2006-01-04
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: Estudio abierto, multicéntrico de acceso expandido de AMN107 oral en pacientes adultos con Imatinib (Glivec®/Gleevec®) para leucemia mieloide crónica intolerante o resistente en crisis blástica o f...
    Medical condition: Leucemia mieloide crónica en fase acelerada, en crisis blástica y en fase crónica Chronic myeloid leukemia in blast crisis, accelerated phase or chronic phase
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) IE (Completed) CZ (Completed) SE (Completed) DK (Completed) BE (Completed) HU (Completed) AT (Completed) DE (Completed) PT (Prematurely Ended) GR (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000657-29 Sponsor Protocol Number: CSTI571K2301 Start Date*: 2005-07-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized open-label study of 400 mg versus 800 mg of Gleevec/Glivec (imatinib mesylate) in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP)...
    Medical condition: Newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP)
    Disease: Version SOC Term Classification Code Term Level
    M15 10009013
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) ES (Completed) IT (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-007054-35 Sponsor Protocol Number: CAMN107A2404 Start Date*: 2009-08-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A RANDOMIZED PHASE III STUDY OF IMATINIB DOSE OPTIMIZATION COMPARED WITH NILOTINIB IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA AND SUBOPTIMAL RESPONSE TO STANDARD-DOSE IMATINIB
    Medical condition: IMATINIB DOSE OPTIMIZATION COMPARED WITH NILOTINIB IN PATIENTS WITH CML AND SUBOPTIMAL RESPONSE TO STANDARD-DOSE IMATINIB
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009012 Chronic myelogenous leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2009-013295-48 Sponsor Protocol Number: 22505 Start Date*: 2009-09-04
    Sponsor Name:Århus University Hospital, Department of Dermatology
    Full Title: Treatment of patients with Nephrogenic Systemic Fibrosis(NSF) with Imatinib Mesylate(Glivec). An open label clinical trial among patients with moderate to severe NSF.
    Medical condition: Nephrogenic Systemic Fibrosis (NSF) is a fibrosing disease strongly associated with Gadolinium Based Contrast Agents(GBCA). Hard dermal plaques appear on legs, arms and abdomen. The lesions involve...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10067467 Nephrogenic systemic fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-001169-32 Sponsor Protocol Number: CA180-035 Start Date*: 2005-11-16
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized Two-Arm, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects with Chronic Myeloid Leukemia in Acce...
    Medical condition: Subjects with Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) or in Myeloid (My) or Lymphoid (Ly) Blast Phase (BP) or with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) HU (Completed) DK (Completed) IE (Completed) CZ (Completed) FI (Completed) ES (Completed) IT (Completed) BE (Completed) DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018419-14 Sponsor Protocol Number: CAMN107A2120 Start Date*: 2010-10-27
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, open-label, pharmacokinetic study of oral nilotinib in pediatric patients with Gleevec® (imatinib)-resistant/intolerant Ph+ CML chronic phase (CP) or accelerated phase (AP) or with ...
    Medical condition: pediatric patients with Gleevec® (imatinib)- resistant/intolerant Ph+ CML chronic phase (CP) or accelerated phase (AP) or with refractory/relapsed Ph+ ALL
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009700 CML LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) DE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012616-40 Sponsor Protocol Number: CAMN107A2405 Start Date*: 2009-08-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An Open Label, Randomized Study of Nilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients with Evidence of Persistent Leukemia by ...
    Medical condition: Chronic Myelogenous Leukemia in Chronic Phase
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009012 Chronic myelogenous leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-001294-99 Sponsor Protocol Number: CA180-034 Start Date*: 2005-07-18
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Ph...
    Medical condition: Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia who are resistant or intolerant to Imatinib Mesylate
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed) GB (Completed) HU (Completed) DK (Completed) IE (Completed) CZ (Completed) FI (Completed) IT (Completed) EE (Completed) ES (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018418-53 Sponsor Protocol Number: CSTI571A2110 Start Date*: 2010-06-01
    Sponsor Name:Novartis Pharma Service AG
    Full Title: A non-randomized, open-label study to characterize the pharmacokinetics of Glivec/Gleevec® (imatinib mesylate) in pediatric (age range 1 to less than 4 years) patients with chronic myeloid leukemia...
    Medical condition: Chronic Myeloid Leukemia (CML) and Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph+ ALL)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009015 Chronic myeloid leukemia LLT
    12.1 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) NL (Prematurely Ended) HU (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003624-37 Sponsor Protocol Number: CA180-188 Start Date*: 2007-11-16
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who are Experiencing Clinical Benefit on Current START or CA180039 Protocols: Lon...
    Medical condition: Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009012 Chronic myelogenous leukemia LLT
    9.1 10034877 Philadelphia chromosome positive LLT
    9.1 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) IE (Completed) GB (Completed) IT (Completed) FI (Completed) ES (Completed) HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 04:53:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA